Uptravi and Diverticulitis aggravated - a phase IV clinical study of FDA data


Diverticulitis aggravated is found among people who take Uptravi, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Uptravi and have Diverticulitis aggravated. It is created by eHealthMe based on reports of 22,185 people who have side effects when taking Uptravi from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 24, 2023

22,185 people reported to have side effects when taking Uptravi.
Among them, 77 people (0.35%) have Diverticulitis aggravated.

What is Uptravi?

Uptravi has active ingredients of selexipag. eHealthMe is studying from 22,190 Uptravi users for its effectiveness, alternative drugs and more.

What is Diverticulitis aggravated?

Diverticulitis aggravated (digestive disease which involves the formation of pouches (diverticula) within the bowel wall-aggravated) is found to be associated with 1,234 drugs and 352 conditions by eHealthMe.

Number of Uptravi and Diverticulitis aggravated reports submitted per year:

Could Uptravi cause Diverticulitis aggravated?

Time on Uptravi when people have Diverticulitis aggravated *:

  • < 1 month: 69.23 %
  • 1 - 6 months: 7.69 %
  • 6 - 12 months: 7.69 %
  • 1 - 2 years: 15.38 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Diverticulitis aggravated when taking Uptravi *:

  • female: 54.55 %
  • male: 45.45 %

Age of people who have Diverticulitis aggravated when taking Uptravi *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 1.54 %
  • 50-59: 16.92 %
  • 60+: 81.54 %

Common drugs people take besides Uptravi *:

  1. Opsumit: 41 people, 53.25%
  2. Adempas: 24 people, 31.17%
  3. Adcirca: 16 people, 20.78%
  4. Eliquis: 16 people, 20.78%
  5. Ambrisentan: 15 people, 19.48%
  6. Metformin: 9 people, 11.69%
  7. Xarelto: 8 people, 10.39%
  8. Aldactone: 6 people, 7.79%
  9. Letairis: 5 people, 6.49%
  10. Lasix: 3 people, 3.90%

Common side effects people have besides Diverticulitis aggravated *:

  1. Diarrhea: 43 people, 55.84%
  2. Headache (pain in head): 42 people, 54.55%
  3. Breathing Difficulty: 23 people, 29.87%
  4. Nausea (feeling of having an urge to vomit): 22 people, 28.57%
  5. Weight Decreased: 19 people, 24.68%
  6. Weakness: 19 people, 24.68%
  7. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 18 people, 23.38%
  8. Dyspnea Exertional: 17 people, 22.08%
  9. Malaise (a feeling of general discomfort or uneasiness): 16 people, 20.78%
  10. Fatigue (feeling of tiredness): 16 people, 20.78%

Common conditions people have *:

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 71 people, 92.21%
  2. Constipation: 6 people, 7.79%
  3. Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 6.49%
  4. High Blood Cholesterol: 5 people, 6.49%
  5. Disease Progression: 3 people, 3.90%
  6. Systemic Sclerosis (Scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin): 1 person, 1.30%
  7. Cardiac Disorder: 1 person, 1.30%
  8. Blood Potassium Decreased: 1 person, 1.30%
  9. Biliary Cirrhosis Primary (primary biliary cirrhosis (pbc) is a long-term liver disease that damages the small bile ducts in the liver. the build-up of bile damages the liver): 1 person, 1.30%

* Approximation only. Some reports may have incomplete information.

Do you take Uptravi and have Diverticulitis aggravated?

Check whether Diverticulitis aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Diverticulitis aggravated and when was it recovered:

Expand to all the drugs that have ingredients of selexipag:

Alternative drugs to, pros and cons of Uptravi:

Common Uptravi side effects:

Browse all side effects of Uptravi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Diverticulitis aggravated treatments and more:

COVID vaccines that are related to Diverticulitis aggravated:

Common drugs associated with Diverticulitis aggravated:

All the drugs that are associated with Diverticulitis aggravated:

Common conditions associated with Diverticulitis aggravated:

All the conditions that are associated with Diverticulitis aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on selexipag (the active ingredients of Uptravi) and Uptravi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: